Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma: A Prospective, Single-Arm, Single-Center, Phase 2 Trial

NCT07461831 is registered in ClinicalTrials.gov with Beijing Tongren Hospital as lead sponsor.

NCT NCT07461831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07461831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma: A Prospective, Single-Arm, Single-Center, Phase 2 Trial
Lead sponsor
Beijing Tongren Hospital
Phase
Phase 2
Overall status
Completed
Start date
February 1, 2022
Completion date
September 29, 2026
Enrollment
74 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

large b-cell lymphoma (lbcl)